Italian survey on cetuximab-based therapy of elderly patients with metastatic colorectal cancer

Gerardo Rosati, Raffaele Addeo, Giuseppe Aprile, Antonio Avallone, Domenico Bilancia, Silvia Brugnatelli, Gabriella Buccafusca, Chiara Carlomagno, Stefano Cordio, Sara Delfanti, Emanuela Dell’Aquila, Maurizio Di Bisceglie, Samantha Di Donato, Antonio Di Stasi, Domenico Germano, Francesco Giuliani, Cristina Granetto, Tiziana Pia Latiano, Silvana Leo, Paolo TralongoMaria Elena Stroppolo, Filippo Venturini, Salvatore Bianco

Research output: Contribution to journalArticle

Abstract

Purpose: There is no consensus on the use of cetuximab in elderly patients with metastatic colorectal cancer. To this end, a survey was carried in 17 Italian oncology centers. Methods: The centers answered a 29-item questionnaire structured as follows: (i) demographic characteristics; (ii) medical history; (iii) assessment of RAS/BRAF mutations and DPD/UGT polymorphism before treatment; (iv) treatment schemes and side effects; (v) geriatric assessment and customization of treatment. Results: One-third of patients are over 80 years old. The RAS/BRAF mutational status is not primarily evaluated by 17.6% of the centers, while DPD and UGT polymorphism is not evaluated by 82.4% and 76.5% of the centers. The most common therapeutic scheme is cetuximab/FOLFIRI and diarrhea is the main cause of suspension/reduction of treatment. The 70% of centers use systemic tetracyclines for skin toxicity. The 23.5% of the centers do not carry out any geriatric evaluation before the start of the therapy and those who perform it prefer the G8 (70.6%) and VES-13 (29.4%) scales. Conclusions: Greater efforts should be made to improve the evaluation of the patient both about mutational and genetic procedures with geriatric evaluation. As for cetuximab in elderly patients, randomized studies are needed to provide guidance to physicians.

Original languageEnglish
Pages (from-to)1089-1096
Number of pages8
JournalCancer Chemotherapy and Pharmacology
Volume84
Issue number5
DOIs
Publication statusPublished - Nov 1 2019

Fingerprint

Geriatrics
Colorectal Neoplasms
Polymorphism
Tetracyclines
Oncology
Toxicity
Suspensions
Skin
Therapeutics
Geriatric Assessment
Cetuximab
Surveys and Questionnaires
Diarrhea
Demography
Physicians
Mutation

Keywords

  • Cetuximab
  • Elderly patients
  • Metastatic colorectal cancer
  • Survey

ASJC Scopus subject areas

  • Oncology
  • Toxicology
  • Pharmacology
  • Cancer Research
  • Pharmacology (medical)

Cite this

Italian survey on cetuximab-based therapy of elderly patients with metastatic colorectal cancer. / Rosati, Gerardo; Addeo, Raffaele; Aprile, Giuseppe; Avallone, Antonio; Bilancia, Domenico; Brugnatelli, Silvia; Buccafusca, Gabriella; Carlomagno, Chiara; Cordio, Stefano; Delfanti, Sara; Dell’Aquila, Emanuela; Di Bisceglie, Maurizio; Di Donato, Samantha; Di Stasi, Antonio; Germano, Domenico; Giuliani, Francesco; Granetto, Cristina; Latiano, Tiziana Pia; Leo, Silvana; Tralongo, Paolo; Stroppolo, Maria Elena; Venturini, Filippo; Bianco, Salvatore.

In: Cancer Chemotherapy and Pharmacology, Vol. 84, No. 5, 01.11.2019, p. 1089-1096.

Research output: Contribution to journalArticle

Rosati, G, Addeo, R, Aprile, G, Avallone, A, Bilancia, D, Brugnatelli, S, Buccafusca, G, Carlomagno, C, Cordio, S, Delfanti, S, Dell’Aquila, E, Di Bisceglie, M, Di Donato, S, Di Stasi, A, Germano, D, Giuliani, F, Granetto, C, Latiano, TP, Leo, S, Tralongo, P, Stroppolo, ME, Venturini, F & Bianco, S 2019, 'Italian survey on cetuximab-based therapy of elderly patients with metastatic colorectal cancer', Cancer Chemotherapy and Pharmacology, vol. 84, no. 5, pp. 1089-1096. https://doi.org/10.1007/s00280-019-03943-x
Rosati, Gerardo ; Addeo, Raffaele ; Aprile, Giuseppe ; Avallone, Antonio ; Bilancia, Domenico ; Brugnatelli, Silvia ; Buccafusca, Gabriella ; Carlomagno, Chiara ; Cordio, Stefano ; Delfanti, Sara ; Dell’Aquila, Emanuela ; Di Bisceglie, Maurizio ; Di Donato, Samantha ; Di Stasi, Antonio ; Germano, Domenico ; Giuliani, Francesco ; Granetto, Cristina ; Latiano, Tiziana Pia ; Leo, Silvana ; Tralongo, Paolo ; Stroppolo, Maria Elena ; Venturini, Filippo ; Bianco, Salvatore. / Italian survey on cetuximab-based therapy of elderly patients with metastatic colorectal cancer. In: Cancer Chemotherapy and Pharmacology. 2019 ; Vol. 84, No. 5. pp. 1089-1096.
@article{bc80c6d484fa4cad983703680708b15e,
title = "Italian survey on cetuximab-based therapy of elderly patients with metastatic colorectal cancer",
abstract = "Purpose: There is no consensus on the use of cetuximab in elderly patients with metastatic colorectal cancer. To this end, a survey was carried in 17 Italian oncology centers. Methods: The centers answered a 29-item questionnaire structured as follows: (i) demographic characteristics; (ii) medical history; (iii) assessment of RAS/BRAF mutations and DPD/UGT polymorphism before treatment; (iv) treatment schemes and side effects; (v) geriatric assessment and customization of treatment. Results: One-third of patients are over 80 years old. The RAS/BRAF mutational status is not primarily evaluated by 17.6{\%} of the centers, while DPD and UGT polymorphism is not evaluated by 82.4{\%} and 76.5{\%} of the centers. The most common therapeutic scheme is cetuximab/FOLFIRI and diarrhea is the main cause of suspension/reduction of treatment. The 70{\%} of centers use systemic tetracyclines for skin toxicity. The 23.5{\%} of the centers do not carry out any geriatric evaluation before the start of the therapy and those who perform it prefer the G8 (70.6{\%}) and VES-13 (29.4{\%}) scales. Conclusions: Greater efforts should be made to improve the evaluation of the patient both about mutational and genetic procedures with geriatric evaluation. As for cetuximab in elderly patients, randomized studies are needed to provide guidance to physicians.",
keywords = "Cetuximab, Elderly patients, Metastatic colorectal cancer, Survey",
author = "Gerardo Rosati and Raffaele Addeo and Giuseppe Aprile and Antonio Avallone and Domenico Bilancia and Silvia Brugnatelli and Gabriella Buccafusca and Chiara Carlomagno and Stefano Cordio and Sara Delfanti and Emanuela Dell’Aquila and {Di Bisceglie}, Maurizio and {Di Donato}, Samantha and {Di Stasi}, Antonio and Domenico Germano and Francesco Giuliani and Cristina Granetto and Latiano, {Tiziana Pia} and Silvana Leo and Paolo Tralongo and Stroppolo, {Maria Elena} and Filippo Venturini and Salvatore Bianco",
year = "2019",
month = "11",
day = "1",
doi = "10.1007/s00280-019-03943-x",
language = "English",
volume = "84",
pages = "1089--1096",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "5",

}

TY - JOUR

T1 - Italian survey on cetuximab-based therapy of elderly patients with metastatic colorectal cancer

AU - Rosati, Gerardo

AU - Addeo, Raffaele

AU - Aprile, Giuseppe

AU - Avallone, Antonio

AU - Bilancia, Domenico

AU - Brugnatelli, Silvia

AU - Buccafusca, Gabriella

AU - Carlomagno, Chiara

AU - Cordio, Stefano

AU - Delfanti, Sara

AU - Dell’Aquila, Emanuela

AU - Di Bisceglie, Maurizio

AU - Di Donato, Samantha

AU - Di Stasi, Antonio

AU - Germano, Domenico

AU - Giuliani, Francesco

AU - Granetto, Cristina

AU - Latiano, Tiziana Pia

AU - Leo, Silvana

AU - Tralongo, Paolo

AU - Stroppolo, Maria Elena

AU - Venturini, Filippo

AU - Bianco, Salvatore

PY - 2019/11/1

Y1 - 2019/11/1

N2 - Purpose: There is no consensus on the use of cetuximab in elderly patients with metastatic colorectal cancer. To this end, a survey was carried in 17 Italian oncology centers. Methods: The centers answered a 29-item questionnaire structured as follows: (i) demographic characteristics; (ii) medical history; (iii) assessment of RAS/BRAF mutations and DPD/UGT polymorphism before treatment; (iv) treatment schemes and side effects; (v) geriatric assessment and customization of treatment. Results: One-third of patients are over 80 years old. The RAS/BRAF mutational status is not primarily evaluated by 17.6% of the centers, while DPD and UGT polymorphism is not evaluated by 82.4% and 76.5% of the centers. The most common therapeutic scheme is cetuximab/FOLFIRI and diarrhea is the main cause of suspension/reduction of treatment. The 70% of centers use systemic tetracyclines for skin toxicity. The 23.5% of the centers do not carry out any geriatric evaluation before the start of the therapy and those who perform it prefer the G8 (70.6%) and VES-13 (29.4%) scales. Conclusions: Greater efforts should be made to improve the evaluation of the patient both about mutational and genetic procedures with geriatric evaluation. As for cetuximab in elderly patients, randomized studies are needed to provide guidance to physicians.

AB - Purpose: There is no consensus on the use of cetuximab in elderly patients with metastatic colorectal cancer. To this end, a survey was carried in 17 Italian oncology centers. Methods: The centers answered a 29-item questionnaire structured as follows: (i) demographic characteristics; (ii) medical history; (iii) assessment of RAS/BRAF mutations and DPD/UGT polymorphism before treatment; (iv) treatment schemes and side effects; (v) geriatric assessment and customization of treatment. Results: One-third of patients are over 80 years old. The RAS/BRAF mutational status is not primarily evaluated by 17.6% of the centers, while DPD and UGT polymorphism is not evaluated by 82.4% and 76.5% of the centers. The most common therapeutic scheme is cetuximab/FOLFIRI and diarrhea is the main cause of suspension/reduction of treatment. The 70% of centers use systemic tetracyclines for skin toxicity. The 23.5% of the centers do not carry out any geriatric evaluation before the start of the therapy and those who perform it prefer the G8 (70.6%) and VES-13 (29.4%) scales. Conclusions: Greater efforts should be made to improve the evaluation of the patient both about mutational and genetic procedures with geriatric evaluation. As for cetuximab in elderly patients, randomized studies are needed to provide guidance to physicians.

KW - Cetuximab

KW - Elderly patients

KW - Metastatic colorectal cancer

KW - Survey

UR - http://www.scopus.com/inward/record.url?scp=85073487029&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073487029&partnerID=8YFLogxK

U2 - 10.1007/s00280-019-03943-x

DO - 10.1007/s00280-019-03943-x

M3 - Article

C2 - 31493178

AN - SCOPUS:85073487029

VL - 84

SP - 1089

EP - 1096

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 5

ER -